Intravenous golimumab in rheumatoid arthritis

被引：9

作者：

Cohen, Marc D. ^{[1
]}

Keystone, Edward C. ^{[2
,3
]}

机构：

[1] Mayo Clin, Denver, CO 80218 USA

[2] Univ Toronto, Toronto, ON, Canada

[3] Mt Sinai Hosp, Toronto, ON M5T 3L9, Canada

来源：

EXPERT REVIEW OF CLINICAL IMMUNOLOGY | 2014年 / 10卷 / 07期

关键词：

anti-TNF-; antibodies; golimumab; rheumatoid arthritis treatment; safety of TNF- inhibition; TNF-; inhibition; ALPHA MONOCLONAL-ANTIBODY; NECROSIS-FACTOR-ALPHA; DOUBLE-BLIND; PHASE-III; ANKYLOSING-SPONDYLITIS; METHOTREXATE THERAPY; SAFETY; EFFICACY; PHARMACOKINETICS;

D O I：

10.1586/1744666X.2014.918847

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Intravenous golimumab in a dosage of 2 mg/kg, initially given every 4 weeks but then every 8 weeks, in addition to methotrexate, is effective in the treatment of patients with rheumatoid arthritis. This weight-based infusion is administered over thirty minutes with an acceptable safety profile. Since it is a relatively new formulation, more time will be required to assess its specific role in the rheumatologists' armamentarium and to appreciate more fully its long-term safety.

引用

页码：823 / 830

页数：8

共 50 条

[1] Golimumab for Rheumatoid Arthritis
Pelechas, Eleftherios
Voulgari, Paraskevi V.
Drosos, Alexandros A.
JOURNAL OF CLINICAL MEDICINE, 2019, 8 (03):
[2] Evaluation of golimumab for the treatment of patients with active rheumatoid arthritis
Tanaka, Yoshiya
Senoo, Asako
Fujii, Hideji
Baker, Daniel
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2016, 12 (03) : 319 - 326
[3] Prescribing Patterns of Intravenous Golimumab for Rheumatoid Arthritis
Brady, Brenna L.
Tkacz, Joseph P.
Lofland, Jennifer
Meyer, Roxanne
Bolge, Susan C.
CLINICAL THERAPEUTICS, 2015, 37 (09) : 2028 - 2036
[4] The effect of golimumab on haemoglobin levels in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis
Furst, Daniel E.
Kay, Jonathan
Wasko, Mary Chester
Keystone, Edward
Kavanaugh, Arthur
Deodhar, Atul
Murphy, Frederick T.
Magnus, Jeanette H.
Hsia, Elizabeth C.
Hsu, Benjamin
Xu, Stephen
Rahman, Mahboob U.
Doyle, Mittie K.
RHEUMATOLOGY, 2013, 52 (10) : 1845 - 1855
[5] Pooled safety results across phase 3 randomized trials of intravenous golimumab in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis
Husni, M. Elaine
Deodhar, Atul
Schwartzman, Sergio
Chakravarty, Soumya D.
Hsia, Elizabeth C.
Leu, Jocelyn H.
Zhou, Yiying
Lo, Kim H.
Kavanaugh, Arthur
ARTHRITIS RESEARCH & THERAPY, 2022, 24 (01)
[6] Immunogenicity of golimumab and its clinical relevance in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis
Leu, Jocelyn H.
Adedokun, Omoniyi J.
Gargano, Cynthia
Hsia, Elizabeth C.
Xu, Zhenhua
Shankar, Gopi
RHEUMATOLOGY, 2019, 58 (03) : 441 - 446
[7] Two-year retention rate of golimumab in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis: data from the LORHEN registry
Manara, M.
Caporali, R.
Favalli, E. G.
Grosso, V.
Atzeni, F.
Sarzi-Puttini, P.
Gorla, R.
Bazzani, C.
Fusaro, E.
Pellerito, R.
Rocchetta, P. A.
Sinigaglia, L.
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2017, 35 (05) : 804 - 809
[8] Golimumab for Rheumatoid Arthritis: A Systematic Review
Singh, Jasvinder A.
Noorbaloochi, Shahrzad
Singh, Gurkirpal
JOURNAL OF RHEUMATOLOGY, 2010, 37 (06) : 1096 - 1104
[9] Effectiveness and safety of intravenous golimumab with and without concomitant methotrexate in patients with rheumatoid arthritis in the prospective, noninterventional AWARE study
Broadwell, Aaron
Schechtman, Joy
Conaway, Douglas
Kivitz, Alan
Shiff, Natalie J.
Black, Shawn
Xu, Stephen
Langholff, Wayne
Schwartzman, Sergio
Curtis, Jeffrey R.
BMC RHEUMATOLOGY, 2023, 7 (01)
[10] Safety, Effectiveness, and Treatment Persistence of Golimumab in Elderly Patients with Rheumatoid Arthritis in Real-World Clinical Practice in Japan
Okazaki, Masateru
Kobayashi, Hisanori
Shimizu, Hirohito
Ishii, Yutaka
Yajima, Tsutomu
Kanbori, Masayoshi
RHEUMATOLOGY AND THERAPY, 2018, 5 (01) : 135 - 148

← 1 2 3 4 5 →